NASDAQ:NVCT

Nuvectis Pharma Q2 2026 Earnings Results & Report

Nuvectis Pharma logo
$20.29 +1.09 (+5.68%)
Closing price 04:00 PM Eastern
Extended Trading
$20.88 +0.59 (+2.91%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvectis Pharma missed analyst earnings expectations in its Q2 2026 results, released August 4, 2026. The company reported EPS of -$0.30 versus the -$0.2620 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Nuvectis Pharma EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.2620
Beat/Miss
Missed by -$0.0380
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Nuvectis Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvectis Pharma Q2 2026 Earnings FAQ

Nuvectis Pharma (NASDAQ:NVCT) reported earnings of -$0.30 per share for Q2 2026, missing the consensus estimate of -$0.2620. The report was announced on Tuesday, August 4, 2026.

Nuvectis Pharma Earnings Headlines

Nuvectis Pharma (NASDAQ:NVCT) Stock Jumps 12.5% - Here's Why
FY2026 EPS Estimate for Nuvectis Pharma Decreased by Analyst
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Nuvectis Pharma Inc
Nuvectis (NVCT) Q3 2026 Earnings Call Transcript
See More Nuvectis Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvectis Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvectis Pharma and other key companies, straight to your email.

About Nuvectis Pharma

Nuvectis Pharma (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types.

The company’s pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines.

Founded in 2020, Nuvectis is headquartered in Fort Lee, New Jersey. The company is led by co-founder, President and Chief Executive Officer Ron Bentsur.

View Nuvectis Pharma Profile